The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in Multiple Endocrine Neoplasia Type 1 and Related States
Open accessAbstract
CONTEXT: Germline mutation in the MEN1 gene is the usual cause of multiple endocrine neoplasia type 1 (MEN1). However, the prevalence of identifiable germline MEN1 mutations in familial MEN1 cases is only 70%. Some cases may have a germline mutation in another gene such as the p27 cyclin-dependent kinase inhibitor (CDKI). OBJECTIVE: The aim of the study was to investigate cases of MEN1 or related states for germline mutations in all CDKI genes. METHODS: A total of 196 consecutive index cases were selected with clear or suspected MEN1 and no identifiable germline MEN1 mutation. Every case was analyzed for germline mutation in each of the seven CDKI genes. RESULTS: We identified benign polymorphisms of the CDKI genes and also 15 other initially unclassified sequence variants. After detailed gene/protein analysis, seven of these 15 variants were classified as probably pathological mutations. Three of these seven were probable mutations of p27. The remaining four were probable pathological mutations in three of the other CDKI genes, thereby implicating these three genes in the germline of human tumors. The identification rates for probably pathological mutations among the 196 index cases were similarly low for each of four CDKI genes: p15 (1%), p18 (0.5%), p21 (0.5%), and p27 (1.5%). No characteristic clinical subtype related to MEN1 was identified among the seven index cases and their families. CONCLUSION: Rare germline mutation in any among four (p15, p18, p21, and p27) of the seven CDKIs is a probable cause of MEN1 or of some related states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex
Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., & Pavletich, N. P. (1996) · Nature · doi:10.1038/382325a0 · Cited by 907
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Tumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699
Lemos, M. C., & Thakker, R. V. (2008) · Human Mutation · doi:10.1002/humu.20605 · Cited by 675
Germ-line mutations in p27 Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans
Pellegata, N. S., Quintanilla-Martinez, L., Siggelkow, H., Samson, E., Bink, K., Höfler, H., Fend, F., Graw, J., & Atkinson, M. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603877103 · Cited by 644
Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene
Vierimaa, O., Georgitsi, M., Lehtonen, R., Vahteristo, P., Kokko, A., Raitila, A., Tuppurainen, K., Ebeling, T. M. L., Salmela, P. I., Paschke, R., et al. (2006) · Science · doi:10.1126/science.1126100 · Cited by 618
Easton, D. F., Deffenbaugh, A. M., Pruss, D., Frye, C., Wenstrup, R. J., Allen-Brady, K., Tavtigian, S. V., Monteiro, A. N. A., Iversen, E. S., Couch, F. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/521032 · Cited by 455
Multiple endocrine neoplasia type 1.
Pannett, A. A., & Thakker, R. V. (1999) · Endocrine-related cancer · doi:10.1677/erc.0.0060449 · Cited by 345
Franklin, D. S., Godfrey, V. L., O'Brien, D. A., Deng, C., & Xiong, Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6147-6158.2000 · Cited by 297
Philipp-Staheli, J., Payne, S. R., & Kemp, C. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5143 · Cited by 293
Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia
Georgitsi, M., Raitila, A., Karhu, A., van der Luijt, R. B., Aalfs, C. M., Sane, T., Vierimaa, O., Mäkinen, M. J., Tuppurainen, K., Paschke, R., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2843 · Cited by 283
de Leon, M. P. (1994) · Recent Results in Cancer Research · doi:10.1007/978-3-642-85076-9_7 · Cited by 260
Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
Jeffrey, P. D., Tong, L., & Pavletich, N. P. (2000) · Genes & Development · doi:10.1101/gad.851100 · Cited by 239
Lam, W. W. K., Hatada, I., Ohishi, S., Mukai, T., Joyce, J. A., Cole, T. R. P., Donnai, D., Reik, W., Schofield, P. N., & Maher, E. R. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.7.518 · Cited by 179
Cyclins and CDKS in development and cancer: lessons from genetically modified mice
Santamaria, D. (2006) · Frontiers in Bioscience · doi:10.2741/1871 · Cited by 165
Familial melanoma, pancreatic cancer and germline CDKN2A mutations
Goldstein, A. M. (2004) · Human Mutation · doi:10.1002/humu.9247 · Cited by 130
Meningiomas May Be a Component Tumor of Multiple Endocrine Neoplasia Type 1
Asgharian, B., Chen, Y., Patronas, N. J., Peghini, P. L., Reynolds, J. C., Vortmeyer, A. O., Zhuang, Z., Venzon, D. J., Gibril, F., & Jensen, R. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0938-3 · Cited by 123
Recessive transmission of a multiple endocrine neoplasia syndrome in the rat.
Fritz, A., Walch, A. K., Piotrowska, K., et al. (2002) · PubMed · Cited by 121
Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis
Bai, F., Pei, X., Godfrey, V., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1269-1277.2003 · Cited by 105
Cell cycle control of pituitary development and disease
Quereda, V., & Malumbres, M. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0146 · Cited by 103
Ozawa, A., Agarwal, S. K., Mateo, C. M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2563 · Cited by 87
Self-citationGreenblatt, M. S., Beaudet, J. G., Gump, J., Godin, K. S., Trombley, L. M., Koh, J., & Bond, J. P. (2003) · Oncogene · doi:10.1038/sj.onc.1206101 · Cited by 76
Ruas, M., Brookes, S., McDonald, N. Q., & Peters, G. G. (1999) · Oncogene · doi:10.1038/sj.onc.1202918 · Cited by 76
Molecular genetics of neuroendocrine tumors
Duerr, E., & Chung, D. C. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.12.001 · Cited by 70
A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.
Bhatia, K. G., Fan, S., Spangler, G., Weintraub, M., O'Connor, P. M., Judde, J., & MAGRATH, I. T. (1995) · PubMed · Cited by 66
p27 Kip1 Inhibition of GRB2-SOS Formation Can Regulate Ras Activation
Moeller, S. J., Head, E. D., & Sheaff, R. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.11.3735-3752.2003 · Cited by 64
Genetic Analysis of Mammalian Cyclin-Dependent Kinases and Their Inhibitors
Malumbres, M., Ortega, S., & Barbacid, M. (2000) · Biological Chemistry · doi:10.1515/bc.2000.105 · Cited by 56
p21Cip1 nullizygosity increases tumor metastasis in irradiated mice.
Jackson, R. J., Engelman, R. W., Coppola, D., Cantor, A. B., Wharton, W., & Pledger, W. J. (2003) · PubMed · Cited by 56
Baumgartner, R., Fernandez-Catalan, C., Winoto, A., Huber, R., Engh, R. A., & Holak, T. A. (1998) · Structure · doi:10.1016/s0969-2126(98)00128-2 · Cited by 51
p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia
Komuro, H., Valentine, M. B., Rubnitz, J. E., Saito, M., Raimondi, S. C., Carroll, A. J., Yi, T., Sherr, C. J., & Look, A. T. (1999) · Neoplasia · doi:10.1038/sj.neo.7900033 · Cited by 41
Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma
Arap, W., Knudsen, E. S., Wang, J. Y. J., Cavenee, W. K., & Huang, H.-J. S. (1997) · Oncogene · doi:10.1038/sj.onc.1200870 · Cited by 33
Noh, S. J., Li, Y., Xiong, Y., & Guan, K. (1999) · PubMed · Cited by 30
Multiple Endocrine Neoplasia Type 1
Brandi, M. L., Bordi, C., Tonelli, F., Falchetti, A., & Marx, S. J. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50160-8 · Cited by 2
Self-citation
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Pathogenesis of pituitary tumors
Melmed, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.40 · Cited by 466
Beckers, A., Aaltonen, L. A., Daly, A. F., & Karhu, A. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1013 · Cited by 360
Metadata
- Authors
- Agarwal, S. K., Mateo, C. M., & Marx, S. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-05-01
- Volume
- 94
- Issue
- 5
- Pages
- 1826-1834
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2034596576
- Cited by
- 318
- References
- 35
- FWCI
- 16.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.